2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $34M | $59M | $96M | $123M | $163M |
Cost of Revenue | $2.6M | $5.8M | $12M | $17M | $359K |
Gross Profit | $31M | $53M | $85M | $106M | $162M |
Gross Profit % | 92% | 90% | 88% | 86% | 100% |
R&D Expenses | $0.0063 | $0.054 | $0.089 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $212K | $3.2M | $8.2M | $6.8M | -$12M |
Dep. & Amort. | $15M | $31M | $50M | $64M | $77M |
Def. Tax | -$3.5M | $104K | $0 | $0 | $0 |
Stock Comp. | $2.5M | $3.7M | $4.8M | $4.8M | $5.7M |
Chg. in WC | -$30K | $676K | -$5M | $2.5M | -$2.1M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $93M | $7.6M | $71M | $18M | $14M |
ST Investments | $253K | $4.3M | $24M | $0 | $0 |
Cash & ST Inv. | $93M | $7.6M | $71M | $18M | $14M |
Receivables | $2.9M | $5.1M | $46M | $134M | $139M |
Inventory | -$253K | -$4.3M | -$8.7M | $0 | $0 |
NTST achieved a record quarter with $195 million in gross investments at a blended cash yield of 7.4%, including three development projects and a development pipeline of $14.6 million.
The company reported Q4 2024 Core FFO of $26.5 million ($0.32 per share) and AFFO of $25.9 million ($0.32 per share), reflecting a 3.2% year-over-year increase. Full-year 2024 AFFO grew 3.3% to $1.26 per share.
NTST introduced 2025 AFFO guidance of $1.27 to $1.30 per share, with expected net investment activity between $75 million and $125 million and cash G&A expenses ranging from $14.5 million to $15.5 million.
The company continues to diversify its portfolio, reducing top tenant concentrations, with a goal of having no tenant above 5% of ABR by year-end 2025. Walgreens exposure has already decreased to 3.8% of ABR.
NTST closed on $275 million in additional financing commitments, including a $175 million term loan at a fixed rate of 5.12% and an upsized $500 million revolving credit facility, extending debt maturities and improving financial flexibility.